1	Longitudinal proteomic investigation of COVID-19 vaccination
2	
3	Yingrui Wang <sup>1,2,3,4,#</sup> , Qianru Zhu <sup>6,7,#</sup> , Rui Sun <sup>1,2,3,4,#</sup> , Xiao Yi <sup>1,2,3,5,#</sup> , Lingling
4	Huang⁵, Yifan Hu⁵, Weigang Ge⁵, Huanhuan Gao <sup>1,2,3,4</sup> , Xinfu Ye⁵, Yu Song <sup>8</sup> , Li
5	Shao <sup>6,9</sup> , Yantao Li⁵, Jie Li <sup>10,11,</sup> *, Tiannan Guo <sup>1,2,3,4,</sup> *, Junping Shi <sup>6,12,</sup> *
6	
7	<sup>1</sup> Westlake Intelligent Biomarker Discovery Lab, Westlake Laboratory of Life Sciences
8	and Biomedicine, Hangzhou 310024, Zhejiang, China;
9	<sup>2</sup> Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural
10	Biology of Zhejiang Province, School of Life Sciences, Westlake University,
11	Hangzhou 310024, Zhejiang Province, China;
12	<sup>3</sup> Institute of Basic Medical Sciences, Westlake Institute for Advanced Study,
13	Hangzhou 310024, Zhejiang Province, China;
14	<sup>4</sup> Center for Infectious Disease Research, Westlake University, 18 Shilongshan Road,
15	Hangzhou 310024, Zhejiang, China;
16	<sup>5</sup> Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou 310024, China;
17	<sup>6</sup> Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou
18	Normal University, Hangzhou, Zhejiang, China;
19	<sup>7</sup> State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese
20	Medicine, Macau University of Science and Technology, Macau, P.R. China;
21	<sup>8</sup> The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University,
22	Hangzhou, Zhejiang, China;
23	<sup>9</sup> Medical college of Hangzhou Normal University, Hangzhou, Zhejiang, China;
24	<sup>10</sup> Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated
25	Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China;
26	<sup>11</sup> Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu,
27	China;
28	<sup>12</sup> Department of Infectious & Hepatology Diseases, The Affiliated Hospital of
29	Hangzhou Normal University, Hangzhou, Zhejiang, China.
30	<sup>#</sup> These authors contributed equally.
31	*Correspondence: lijier@sina.com ; guotiannan@westlake.edu.cn ;
32	20131004@hznu.edu.cn
33	
34	

35

# 36 Abstract

- 37 Although the development of COVID-19 vaccines has been a remarkable success,
- 38 the heterogeneous individual antibody generation and decline over time are unknown
- and still hard to predict. In this study, blood samples were collected from 163
- 40 participants who next received two doses of an inactivated COVID-19 vaccine
- 41 (CoronaVac<sup>®</sup>) at a 28-day interval. Using TMT-based proteomics, we identified 1715
- 42 serum and 7342 peripheral blood mononuclear cells (PBMCs) proteins. We proposed
- 43 two sets of potential biomarkers (seven from serum, five from PBMCs) using
- 44 machine learning, and predicted the individual seropositivity 57 days after vaccination
- 45 (AUC = 0.87). Based on the four PBMC's potential biomarkers, we predicted the
- 46 antibody persistence until 180 days after vaccination (AUC = 0.79). Our data
- 47 highlighted characteristic hematological host responses, including altered lymphocyte
- 48 migration regulation, neutrophil degranulation, and humoral immune response. This
- 49 study proposed potential blood-derived protein biomarkers for predicting
- 50 heterogeneous antibody generation and decline after COVID-19 vaccination,
- 51 shedding light on immunization mechanisms and individual booster shot planning.
- 52 **Running head:** Longitudinal proteomic profiling of COVID-19 vaccination

# 53 Keywords

54 COVID-19, vaccination, proteomics, neutralizing antibodies (NAbs), machine learning

# 55 Abbreviations

- 56 AGC (automatic gain control), AUC (area under curve), B-H (Benjamini-Hochberg),
- 57 COVID-19 (coronavirus disease 2019), CV (coefficients of variance), DEPs
- 58 (differentially expressed), ECM (extracellular matrix), FDR (false discovery rate),
- 59 GMT (Geometric Mean Titers), GSVA (gene-set variation analysis), IFN (interferon),
- 60 MALFD (metabolic associated fatty liver disease), PBMCs (peripheral blood
- 61 mononuclear cells), SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2),
- 62 SHAP (SHapley Additive exPlanations), T2DM (Type 2 diabetes mellitus)

# 63 Highlights

- Longitudinal proteomics of PBMC and serum from individuals vaccinated with
   CoronaVac<sup>®</sup>.
- 66 2. Machine learning models predict neutralizing antibody generation and decline
- 67 after COVID-19 vaccination.
- 68 3. The adaptive and the innate immune responses are stronger in the seropositive
- 69 groups (especially in the early seropositive group).
- 70 4. Vaccine-induced immunity involves in lymphocyte migration regulation,
- neutrophil degranulation, and humoral immune response.

# 72 Introduction

The global public health crisis and the social disruption caused by the coronavirus 73 disease 2019 (COVID-19) pandemic have prompted the emergency use of speedily 74 developed vaccines. As of October 2022, over 12 billion doses had been 75 administered globally (WHO, 2022-10-25), although the vaccination distribution is 76 significantly unbalanced (van der Graaf et al., 2022). Previous studies have reported 77 that NAbs responses elicited by an inactivated vaccine (CoronaVac®) and an mRNA 78 79 vaccine (BNT162b2) persisted for 6-8 months after full-schedule vaccination and declined to varying degrees (Falsey et al., 2021; Zeng et al., 2021). Therefore, 80 multiple vaccine boosters and prolonged intervals between vaccine doses are 81 needed to maintain the immunity against SARS-CoV-2 (Zhao et al., 2022), and could 82 induce a robust humoral immune response (Ai et al., 2022). Several studies reported 83 the dynamics of NAbs generation and the molecules dysregulation occurring after 84 vaccinations (Liu et al., 2021; Wang et al., 2022). In a BMJ meta-analysis has shown 85 that seroconversion rates and antibody titers after COVID-19 vaccines are 86 significantly lower in immunocompromised patients than immunocompetent 87 individuals (Lee et al., 2022), including immune-mediated inflammatory disorders, 88 solid cancers, organ transplant recipients and hematological cancers. While to the 89 best of our knowledge based on literature search, no study has systematically 90 91 reported heterogeneous hematological host responses to vaccination in both PBMCs and serum. There is currently no known biomarker for predicting the effectiveness of 92 vaccines. 93 In this study, we investigated the host response to Sinovac-CoronaVac<sup>®</sup>. Specifically, 94 we analyzed the proteome of the peripheral blood mononuclear cells (PBMCs) and 95 the sera of a vaccination recipients at different time points. We developed a method 96 97 to predict the host responses to vaccination. Specifically, we predicted who cannot generate antibodies and whose NAbs tend to disappear earlier than six months after 98 99 the vaccination. This information would help plan targeted boosters and decide the 100 types and intervals of the vaccinations.

101

### 102 **Results**

### 103 Clinical and proteomics profiling before inactivated SARS-CoV-2 vaccination

Between January and February 2021, a total of 163 vaccination recipients were 104 recruited in the discovery (N = 137) and the test (N = 26) cohorts (Figures 1A and 105 1B). The average age was 39.8 years in the discovery cohort and 41.6 years in the 106 test cohort. Besides, most indexes of biochemical and hematology were not 107 significantly different between the two cohorts. More details are shown in Tables 1-2, 108 Table S1, and Figure S1. All the participants received the first dose of CoronaVac<sup>®</sup> at 109 day 0 (D0) and the second after 28 days (D28). The qualitative detection of SARS-110 CoV-2 NAbs and spike-specific IgG was done at D0, D28, day 57 (D57), and day 180 111 112 (D180). By D28, 19.6% of all participants (N = 32) were NAb seropositive (Group 2, the early seropositive group). By D57, the percentage of seropositive participants 113

medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

reached 88.3% (N = 144; Group 1+2, which included Group 1, the late seropositive 114 group). The remaining 11.7% (N = 19) still had seronegative results (Group 0, the 115 seronegative group). Within Group 1+2, 33.1% (N = 42) were still positive at D180 116 (Group 4, the persistently seropositive group), while the remaining ones became 117 seronegative (Group 3) (Figure 1A). Besides, 10% of participants in Group 0 were 118 IgG seropositive on day 28, which rising to 100% by day 57 and decreasing to 83% 119 by day 180. However, 30% of participants in Group 1+2 were IgG seropositive on day 120 28, which rising to 100% by day 57 and decreasing to 88% by day 180 (Figure 1C). 121 According to multivariable logistic regression analysis, we found that NAb titers at 122 D28 were positively associated with seropositivity of neutralizing antibodies at D57 123 after adjusting age, sex, BMI and diastolic blood pressure. Then, we also identified 124 that NAb titers at D28 and D57 could as independent predictors for seropositive of 125 126 D180 after adjusting covariates (Figure S1). Blood samples were collected from all participants before their first vaccine dose, then at D28 and D57. Serum and PBMCs 127 were extracted from all blood samples for proteomic profiling. 128 TMT-based analysis involved 528 samples, including pooled controls for aligning 129 130 data from different batches to evaluate quantitative accuracy, and technical replicates 131 for evaluating the reproducibility of the assay or technique. These samples were distributed into 33 batches from three time points: D0, D28, and D57. We quantified 132 7342 PBMC proteins and 1715 serum proteins (Table S2; Figures 1A and S2A). The 133 median coefficients of variance (CV) for the pooled samples were 15.35% and 134 19.32% for the PBMC and the serum data, respectively (Figure S2B). The Pearson 135

correlation coefficients of the technical replicates were 98.09% and 96.82% for 136

PBMC and serum, respectively (Figure S2C). These results showed the robustness 137

of our data and its relatively high consistency and reproducibility. 138

#### 139 Machine learning model for predicting the antibody generation

We next developed a set of models for predicting the seropositivity of individuals 57 140 141 days after their first vaccination dose and 28 days after their second one (at D57) 142 based on the proteomics and clinical indicators collected prior to both doses (at D0). Machine learning models were developed using XGBoost (Chen and Guestrin, 143 2016) (Figure 2A). Proteins or clinical indicators with a significant difference (p-value 144 < 0.05) between the two classes and with  $|\log_2(fold change)| > 0.25$  in the discovery 145 dataset were included in our final feature set. Then, some sparse proteins (NA rate > 146 50%) were also removed. We optimized the models' parameters in the discovery 147 dataset (Cohort 1), and generated a model based on the five PBMC proteins and 148 another based on the seven serum proteins. Using the test cohort (Cohort 2), the 149 PBMC model achieved an Areas Under the Curve (AUC) score of 0.84, while the 150 151 serum one of 0.82 (Figure 2A). Next, we developed an ensemble model combining 152 these two models, which led to better performance (AUC = 0.87) (Figure 2A). Five PBMC proteins (UNC45A, IGHM, FADD, NCK2, and DCPS) and seven serum 153 proteins (SERPINA10, SOD3, LTA4H, SPP2, NAGLU, APLP2, and CHRDL2) were 154 selected for our machine learning models. Most of the above PBMC biomarkers are 155 expressed in immune cells, including B cells, macrophages, natural killer (NK) cells, 156

157 and dendritic cells (HPA; Karlsson et al., 2021). They are thus associated with both innate and adaptive immunity (Figures 2B, 2D). In particular, UNC45A acts as a co-158 159 chaperone for HSP90 promoting progesterone receptor function in the cell, and is required for the NK cell cytotoxicity via lytic granule secretion's control (lizuka et al., 160 2015). IGHM is the constant region of immunoglobulin heavy chains and mediates 161 the effector phase of humoral immunity, which eliminates the bound antigens, FADD 162 is an adaptor molecule that interacts with various cell surface receptors, mediates 163 164 cell apoptotic signals, and is essential in early T cell development (Kabra et al., 165 2001). The seven serum biomarkers are associated with immunity and metabolism (Figures 2C and 2E): SERPINA10 and SPP2 are secreted proteins associated with 166 coagulation and metabolism; LTA4H is enriched in Kupffer cells, monocytes, and 167 neutrophils; NAGLU is mainly expressed in most immune cells; SOD3 and CHRDL2 168 can interact with the extracellular matrix (ECM) organization (HPA; Karlsson et al., 169 170 2021). Based on our three models, only two participants from the test cohort (Nos. 209 and 171 233) were mispredicted. Possibly, their predictions were affected by their drug 172 173 treatments. Specifically, participant No. 209 was incorrectly predicted to be 174 seronegative. This may be due to the long-term treatment with simvastatin and rosuvastatin against hyperlipidemia, which have been suggested to enhance the 175 176 immune response (Guerra-De-Blas et al., 2019; Karmaus et al., 2019). Participant No. 233, whose atherosclerosis was treated with bisoprolol fumarate before 177 vaccination, was predicted to be seropositive despite being seronegative at D57. 178 179 Despite these two mispredictions, our results showed that PBMC and serum proteomics could well predict the individual host responses after vaccination. 180 In addition, predicting those being negative at D28 and then converting (Group 1) or 181 182 never converting (Group 0) could allow for the earlier switch to another vaccine. Similarly, we developed a set of models based on proteins at D0 and achieved an 183 AUC score of 0.843 (PBMC model), 0.847 (serum model) and 0.853 (ensemble 184 model combining these two models) to predict the individual host responses after 185

vaccination (Figures S3A-C). 186

#### 187 Increased innate and adaptive immunity in the seropositive group

We next explored the differences between the seropositive and the seronegative 188 189 groups using the PBMC data. Thirty-eight proteins were differentially expressed (DEPs) within the PBMC proteome between the two groups at three time points 190 (Benjamini-Hochberg (B-H) adjusted p-value < 0.05,  $|\log_2(fold change)| > 0.25$ ) 191 (Table S3, Figures 3A and 3B). In particular, 33 proteins were dysregulated at D0 or 192 193 D28. This result suggests that the immune system of the two groups was different at baseline (D0) and was most strongly activated during the early stage after 194 195 vaccination. A gene-set variation analysis (GSVA) was then used to identify the most significantly 196 enriched pathways in the seropositive and the seronegative groups. The resulting 197 198 pathways (B-H adjusted p-value < 0.05,  $|\log_2(fold change)| > 0.25$ ) were mainly

- involved in the immune system. They included the IFNy, IFNa and IFNb signaling, 199
- 200 RNA and DNA modulation, and metabolic pathways. Most of these pathways were
- upregulated in the seropositive group (Figure 3C). 201

202 The DEPs among the three immune response groups – Group 0, Group 1, and Group 2 (Figure 1A) – were primarily involved in RNA metabolism, cellular 203 204 processes, and cytoskeleton regulation-related pathways (Figures S4A-D). Therefore, the dysregulation of these proteins may have contributed to elevated 205 immunity. This agrees with the functional analysis between the seropositive and the 206 seronegative groups. Over 80% of DEPs observed between Group 1 and Group 0 207 were also detected in the comparison between seropositive (Group 1+2) and 208 209 seronegative (Group 0) groups (Figures S3D, S3E and Table S3). 210 We next analyzed the immune cells composition of the PBMCs in our experiment 211 using the deconvolution algorithm of CIBERSORT (Newman et al., 2015). The seropositive group showed an increase in memory B cells and a reduction of naïve B 212 cells (Figure 3D). In addition, CD8<sup>+</sup> T cells and activated memory CD4<sup>+</sup> T cells were 213 significantly higher in the seropositive group than in the seronegative one at D0. The 214 215 adaptive immune responses were thus significantly enhanced at the baseline in the seropositive group (Figure 3E). At D57, the memory B cells and the CD8<sup>+</sup> T cells 216 showed an upward trend over time and were significantly higher in the seropositive 217 218 group. This result is consistent with the reported host responses to SARS-CoV-2 219 infection and vaccination (Chen et al., 2021; Sette and Crotty, 2021). Furthermore, some innate immune cells, such as monocytes, activated NK cells, and activated 220 dendritic cells, also increased over time in the seropositive group (Figure 3E). 221 222 Moreover, the early seropositive group showed increased memory B cells, activated NK cells, M1 and M2 macrophages (Figures S4F-G). These results show that the 223 proportion of SARS-CoV-2-specific memory lymphocytes may increase after 224 vaccination with CoronaVac®. 225

#### 226 The interaction between metabolism and immunity is linked with

#### seroconversion 227

We next investigated the differences between the seropositive and the seronegative 228 229 groups using the serum data. A total of 13 DEPs were found at D0 and D28, and two at D57 (B-H adjusted p-value < 0.05,  $|\log_2(fold change)| > 0.25$ ) (Table S3, Figures 230 4A-B). In line with our findings from the PBMC data, more DEPs were identified at D0 231 and D28 than at D57. All the DEPs were upregulated in the seropositive group 232 233 except TTR. Misfolding and aggregation of TTR, causing amyloid thyroxine protein amyloidosis, has been reported associated with a higher risk of COVID-19 morbidity 234 and mortality (Brannagan et al., 2021). This finding is consistent with our results, as 235 236 TTR was downregulated in the seropositive group. Many of our serum DEPs are secreted proteins and include components of the immunoglobulin family: IGKV1-8. 237 IGKV1-16, and IGHV3-15 (Schroeder and Cavacini, 2010). 238 239 Further functional analyses were performed on the DEPs between the seropositive and the seronegative groups, and among the three immune response groups. The 240 significantly enriched functions were neutrophil degranulation, acute phase response 241 242 signaling, and hemostasis (Figures 4B-C, S5A-B, Table S4). It has been shown that the enriched apolipoprotein family could induce the activation of leukocytes, 243 especially the degranulation of neutrophils (Botham and Wheeler-Jones, 2013). Our 244

245 analyses showed that 15 out of the 17 proteins involved in plasma lipoprotein medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

246 remodeling and six out of the eight proteins involved in neutrophil degranulation were

upregulated in the seropositive groups (Figure 4C). This finding suggests that the 247

248 interaction of metabolism and immunity is closely linked with seroconversion.

#### Predicting individual antibody persistence to guide booster shot planning 249

To predict whether the antibodies produced after the CoronaVac® vaccination could 250 251 last for at least 180 days, we generated machine learning models based on the 252 proteomics data and the clinical indicators collected prior to vaccination. In this analysis, we excluded participants from Group 0 (the seronegative ones) and those 253 without clinical indicators on D180. Then the remaining two cohorts (Table 2) were 254 255 the discovery cohort (Cohort 3, N = 107) and the test cohort (Cohort 4, N = 20). Similar as before, proteins with a significant difference (p-value < 0.05) between two 256 classes and with |log<sub>2</sub>(fold change)| > 0.25 in the discovery dataset were included in 257 our final feature set. Then, some proteins (NA rate > 50%) were removed. We 258 optimized the models' parameters in the discovery dataset. An AUC score of 0.79 259 260 was obtained using only the PBMC proteins (Figure 5A), indicating that PBMC 261 proteomics had an excellent prediction ability of the antibody response after both 57 262 and 180 days.

The four PBMC biomarkers (PYCARD, MTMR2, PPCDC, and BRAF) selected by 263 machine learning showed different expression patterns of the immune cells between 264

Groups 3 and 4 (Figure 5C). In particular, PYCARD and PPCDC are mainly 265

expressed in innate immune cells, like monocytes and dendritic cells. MTMR2 and 266

267 BRAF, on the other hand, are expressed in innate and adaptive immune cells,

including NK cells, monocytes, T cells, and B cells (Figure 5D). 268

269 However, seven participants were incorrectly predicted using this model. Specifically, 270 participants Nos. 209 and 216 were incorrectly classified, probably because they 271 both received simvastatin and rosuvastatin (Guerra-De-Blas et al., 2019; Karmaus et al., 2019). In addition, three participants (Nos. 212, 222, and 225) with fatty liver 272

disease and metabolic abnormalities were also wrongly predicted, probably due to 273

274 their metabolic conditions. No. 226 was misclassified because of receiving dexamethasone and amoxicillin. 275

#### Discussion 276

#### 277 Predicting the host response to CoronaVac<sup>®</sup> vaccination using a machine learning model 278

We conducted a TMT-based proteomics analysis to profile the PBMC and serum 279 features that could affect the response to the CoronaVac® vaccination. Using a set of 280 biomarkers measured before vaccination, we built three models to predict individual 281 NAb levels at D57 and another model to predict the persistence of NAbs until at least 282 D180. These potential biomarkers, which were used to distinguish different host 283 responses, were validated using an independent cohort, confirming that the changes 284 285 in PBMC and serum proteins reflect the pathophysiological differences between seropositive and seronegative subjects. 286

All rights reserved. No reuse allowed without permission.

# 287 Potential biomarkers for vaccine-induced antibody generation and persistence

The proteins used by our machine learning classifiers contain several known 288 biomarkers for COVID-19 severity or viral infections. Of note, SERPINA10, 289 predominantly expressed in the liver and subsequently secreted into plasma, inhibits 290 the activity of the coagulation factors Xa and XIa in the presence of protein Z. 291 292 calcium, and phospholipids (Han et al., 2000). SERPINA10 is a known discriminating 293 feature between severe and non-severe COVID-19 (Shen et al., 2020), and can be 294 used as a classifier of disease severity (Messner et al., 2020). Specifically, it is upregulated in the severe COVID-19 cases. In our data, SERPINA10 was 295 downregulated in the seropositive group with a negative SHapley Additive 296 exPlanations (SHAP) value (Figures 2C and 2E). This result further highlights the 297 298 role of coagulation during COVID-19 vaccination and indicates that SERPINA10 may contribute to reducing antibody generation. SOD3, an antioxidant enzyme, has been 299 reported to be downregulated in the urine of severe COVID-19 cases (Bi et al., 300 301 2021). In our study, SOD3 was significantly upregulated in the seropositive group 302 with a positive SHAP value, indicating that SOD3 may promote antibody generation. PYCARD, a key mediator of apoptosis and inflammation, is mainly involved in the 303 304 innate immune response (Wang et al., 2017). It also contributes to T-cell immunity stimulation and cytoskeletal rearrangements coupled to chemotaxis and antigen 305 uptake during adaptive immunity (de Souza et al., 2021). We found PYCARD was 306 307 upregulated in the seropositive group with a positive SHAP value (Figures 5B-C). And thus, we suggest this protein may also promote antibody persistence. These 308 potential biomarkers may promote or reduce antibody generation or persistence, 309 310 providing therapeutic guidance for vaccination strategy.

### 311 Mechanisms behind vaccine-induced immunity

312 To investigate the molecular mechanisms behind vaccine-induced immunity, we

313 integrated our proteomics analyses and thus generated a summary of the

314 dysregulated pathways between the seropositive and the seronegative groups

315 (Figures 6, S6-7).

### 316 Neutrophil degranulation

317 In our data, we found several proteins involved in activating the neutrophil degranulation-based innate immunity, in particular, LTA4H, LTF, MMP9, TTR, CAP1, 318 PYCARD, and GDI2. Specifically, MMP9, LTF, and CAP1 were upregulated at D28 in 319 the seropositive group. Previous studies have shown that the release of MMP9 from 320 321 neutrophils stimulates the migration of inflammatory cells and promotes inflammation 322 and the degradation of the alveolar-capillary barrier (Davey et al., 2011). In our 323 seropositive data, MMP9 was upregulated at D28 and then downregulated at D57 (Figure 6C). This result suggests MMP9 may contribute to a reduced antibody 324 generation, and is consistent with this protein being an indicator of respiratory failure 325 (Ueland et al., 2020) and enhanced mortality risk in COVID-19 patients (C et al., 326 2021). Indeed, evidence has shown that neutrophil activation is a hallmark of severe 327 SARS-CoV-2 infection (Meizlish et al., 2021). Therefore, we speculate that a modest 328 329 upregulation of neutrophil degranulation may contribute to immunity activation and

### 330 vice versa.

# 331 *Regulation of lymphocyte migration*

332 Most regulators of leukocyte extravasation and lymphocyte migration were elevated at D0 or during the early stages in the seropositive group: MSN, MMP9, CXCL12, 333 FADD, NCK2, and TMSB10. In particular, MSN interacts with members of the ezrin-334 radixin-moesin family and regulates lymphocyte egress from lymphoid organs 335 (Serrador et al., 1998). TMSB10, CXCL12, and NCK2 regulate the cytoskeleton 336 organization and are involved in transmigration (Figure 6A). By secreting proteases 337 338 like MMP9, leukocytes degrade the basement membrane and penetrate the tissue interstitial spaces (Sternlicht and Werb, 2001). T-cell receptors are activated through 339 the binding by FADD and the interaction with NCK2, consistently with our immune 340 cell analysis (Figure 6C). Except for antigen recognition, T cell migration was 341 positively regulated by CXCL12, FADD, and PYCARD in our seropositive groups. 342 343 Intriguingly, increased FADD at baseline possibly contributed to the enhanced antibody generation at D57 (Figure 2D). Also, higher PYCARD at baseline led to a 344 345 long antibody persistence based on our machine learning models (Figure 5C).

### 346 Humoral immune response

347 The B-cell receptor is a complex of surface immunoglobulin, and some of its accessory molecules, such as IGHM, IGHV3-15, IGKV1-8, and IGKV1-16, were 348 upregulated in our seropositive group (Figure 6C). Following the receptor cross-349 linking, a complex cascade of signaling molecules results in NF-kB complex and B-350 cell receptor activation. These IgG and cytokines are expressed by JCHAIN and LTF, 351 which were both significantly elevated in our data after vaccination. In addition, 352 several of our overlapping proteins' clusters of PBMC and serum were involved in 353 354 neutrophil degranulation, protein-lipid complex remodeling, platelet degranulation, 355 and complement system (Figures S6-S7). Our data show that the neutrophil 356 degranulation-based activation of the innate immunity, the multiple immune cell migration enhancement, and the humoral immune response activation are 357 dysregulated at baseline and during the early stages after vaccination (Figures 6A-358 359 C).

### 360 **Comparisons with other studies before/after vaccination**

Several studies of COVID-19 vaccination have identified modulation of multiple 361 proteins, metabolites, and gene expression after vaccination (Arunachalam et al., 362 2021; Liu et al., 2021; Zhang et al., 2021; Wang et al., 2022). However, no study has 363 systematically investigated the heterogeneous hematological host responses to 364 365 vaccination in both PBMCs and sera. Neither has any study presented any means to 366 predict the host responses of vaccination. Vaccine-induced protection against 367 COVID-19 may involve NAbs, T-cells, and innate immune mechanisms. In the comparative analysis of multiple vaccines, T cell responses in CoronaVac<sup>®</sup> remains 368 unclear (Sadarangani et al., 2021). Our PBMCs analysis showed that CD8<sup>+</sup> T cells, 369 memory B cells, and activated NK cells were increasingly upregulated in the 370 seropositive group. Previous study showed that mRNA vaccinations can significantly 371

372 enhance the innate immune response, as proven by the greater frequency CD14<sup>+</sup> CD16<sup>+</sup> inflammatory monocytes and higher concentration of plasma IFNy 373 374 (Arunachalam et al., 2021). In our PBMC proteome, monocytes and the IFNy, IFNa and IFNb signaling were elevated in the seropositive groups. A single-cell RNA-375 sequencing study of the PBMCs of healthy subjects revealed that, after CoronaVac® 376 vaccination, the levels of B cells, T cells, NK cells, and myeloid cells better 377 378 resembled those of COVID-19 recovery controls rather than their own before 379 vaccination (Zhang et al., 2021). Similarly, our PBMCs analysis showed that CD8<sup>+</sup> T 380 cells, memory B cells, and activated NK cells were increasingly upregulated in the 381 seropositive group. Consistent with other reports (Wang et al., 2022), our findings support that the humoral immune response, complement activation were induced by 382 CoronaVac<sup>®</sup>. What's unique in the seropositive participants is activated regulation of 383 lymphocyte migration pathway, which suggests enhanced immunity. 384

# 385 Planning booster shot and their benefits

Due to the relatively high effectiveness of booster immunization against severe 386 COVID-19, hospitalization, and even the Omicron variant (Xue et al., 2022), it should 387 388 be strongly supported and administered at the appropriate time. The effectiveness and the safety of boosters have been assessed via large-scale randomized studies 389 and individuals, proving the booster's benefits and the negligible impact of its 390 391 immune-mediated side effects (Zeng et al., 2021). Boosting is particularly important 392 for specific subpopulations: individuals who generate less or shorter-lived NAbs and 393 those who are immunocompromised, such as our seronegative participants (Group 394 0). Moreover, the vaccination strategy may change for recipients with heterologous or homologous vaccinations (Costa Clemens et al., 2022). Our machine learning 395 models predict the seropositivity of individuals at D57 and their NAbs persistence 396 until at least D180 using potential blood-derived protein biomarkers. These tools can 397 establish which populations or individuals may generate enough and persistent 398 399 NAbs, and therefore help plan precise booster administrations. Furthermore, a better balance between primary vaccination and booster may benefit more countries in the 400 401 global fight against COVID-19 (Krause et al., 2021). 402 In summary, we performed a systematic PBMC and serum proteomic study of the 403 heterogeneous hematological host responses to vaccination. We developed a machine learning model based on a panel of proteins expressed at baseline to 404

- 405 predict antibody generation and decline after vaccination. The model can be
- 406 potentially used to identify the individuals of high risk, and guide booster shot, or
- 407 recommendation of other vaccines. Furthermore, our data also provides a panoramic
- 408 view of the molecular changes in PBMCs and serum after vaccination.

# 409 Limitations of the study

410 The findings of this study have to be considered in light of some limitations. First, the

- 411 predictive models need to be further validated in larger cohorts and multicenter
- samples, both biologically and clinically. Second, the explanations for
- 413 misclassifications are not very strong, may because of complex drug history. Third,

All rights reserved. No reuse allowed without permission.

the B cell and T cell responses and the neutralization tests were analyzed in the

415 mixed PBMCs but not assessed *in vitro*.

416

# 417 Acknowledgements

418 This work was supported by the National Natural Science Foundation of China (32200763), Key medical disciplines of Hangzhou, the Medical Health Science and 419 Technology Project of Hangzhou municipal Health Commission (A20210205), the 420 National Key R&D Program of China (2020YFE0202200). The Affiliated Drum 421 Tower Hospital, Medical School of Nanjing University (2022-LCYJ-MS-08). We 422 thank Westlake University Supercomputer Center for assistance in data generation 423 and storage, and the Mass Spectrometry & Metabolomics Core Facility at the 424 425 Center for Biomedical Research Core Facilities of Westlake University for sample

- analysis. We gratefully acknowledge Yi Yu for data analysis, Liqin Qian for editing
- 427 the manuscript.

# 428 Data Availability

429 All mass spectrometry data in this paper are available in the platform iProX at

- https://www.iprox.org/. Project ID: IPX0004305000. All the data will be publicly
   released upon publication. (URL:
- 432 https://www.iprox.cn/page/PSV023.html;?url=1666845005314ZrCF;Password:ZACa)

# 433 Author contributions

434 J.S., T.G., and J.L designed and supervised the project. Q.Z., Y.S., L.S. collected

the samples and clinical data. X.Yi., Y.W., and X.Ye. conducted proteomics

analysis. Y.W., R.S., Q.Z., and X.Yi. performed the experimental design and data

437 interpretation. L.H., Y.W., and W.G. analyzed the proteomics data. Y.H. and Y.L.

438 performed machine learning. Q.Z. analyzed the clinical data. Y.W., Q.Z., R.S., Y.H.,

439 H.G., J.L., T.G., and J.S. wrote the manuscript with inputs from co-authors.

# 440 **Declaration of interest statement**

T.G. is a shareholder of Westlake Omics Inc. X.Yi., L.H., Y.H., W.G., X.Ye. and Y.L.

are employees of Westlake Omics. The remaining authors declare no competing

443 interests in this paper.

# 444 Experimental Procedures

# 445 **Experimental Design and Statistical Rationale**

- The overall goal was systematic investigation of host responses to COVID-19
- 447 vaccines, including the heterogeneity among the recipients, and machine learning

models to predict the effectiveness of vaccination using potential biomarkers at 448

baseline. Subject information for vaccinated recipients is summarized in Tables 1-2. 449

Table S1. Study design of the TMT-Pro labeling-based quantitative proteomics 450

analysis of the PBMCs and sera samples is depicted in Figure 1A and S2A. 451

#### 452 **Participants and Samples**

We recruited 163 vaccination recipients (>18 years) who were not infected with 453 SARS-CoV-2 and some of them had stable chronic medical conditions, including 454 455 hypertension, T2DM, and metabolic fatty liver disease, were eligible to be enrolled from the affiliated hospital of Hangzhou Normal University between January and 456 February 2021, including a discovery (N = 137) and an independent test cohort (N = 457 26). All participants received two doses of CoronaVac® (0.5 mL/dose, Sinovac life 458 science, Beijing, China), an inactivated vaccine against SARS-CoV-2; the second 459 dose 28 days after the first one. Blood samples were collected before vaccination 460 (D0), then 28 (D28), 57 (D57). Blood mononuclear cells and serum were extracted 461 462 from the blood samples. The xenoreactivity was also measured at D0, D28, D57 and

463 180 days after the first dose vaccination (D180). The NAbs for the receptor-binding

domain of the SARS-CoV-2 spike protein were detected using the iFlash 2019-nCoV 464

NAb assay (SHENZHEN YHLO BIOTECH CO., LTD, Shenzhen, China, 465

Cat#C86109), which is a paramagnetic particle chemiluminescent immunoassay for 466 the qualitative detection of SARS-CoV-2 NAbs in human serum and plasma using the 467 automated iFlash immunoassay system; the cut-off value for the antibody was 10.00 468 469 AU/mL.

The participants were classified into three groups based on the xenoreactivity of their 470

NAbs on D28 and Day 57. Specifically, Group 0 included the participants that were 471

seronegative on D28 and D57; Group 1 included the participants that were 472

seronegative on D28 but were seropositive on D57; Group 2 included the participants 473

that were seropositive on D28 and D57. Groups 1 and 2 were then merged into 474

475 Group 1+2 (all the seropositive participants). Group 1+2 was then split into Group 3 (seronegative at D180) and Group 4 (seropositive at D180). 476

This research was approved by the ethical committee of the Affiliated Hospital of 477

Hangzhou Normal University and Westlake University (Hangzhou, China). The study 478

479 was registered in the Chinese Clinical Trial Register (ChiCTR2100042717), and all

participants signed a written informed consent before enrolment. 480

#### Serum and PBMC Protein Extraction and Digestion 481

From each sample, 4 µL of serum were depleted of 14 high abundant serum proteins 482 using a human affinity depletion resin (Thermo Fisher Scientific™, San Jose, USA) 483 and then concentrated into 50 µL through a 3K MWCO filtering unit (Thermo Fisher 484

Scientific<sup>™</sup>, San Jose, USA). More details can be found in the manufacturer's 485

protocols. The resulting serum samples were then prepared for mass spectrometry 486

as described (Shen et al., 2020). Briefly, they were denatured in 8 M urea at 31.5°C 487

for 30 min. Next, the proteins were reduced with 10 mM tris (2-carboxyethyl) 488

phosphine (TCEP) and then alkylated with 40 mM iodoacetamide (IAA). Finally, the 489

protein extracts were diluted and digested using a double step trypsinization for 16 490

491 hours totally (Hualishi Tech. Ltd, Beijing, China).

PBMCs were prepared as previously described (Gao et al., 2020). Briefly, 30 µL of 492

- lysis buffer in 100 mM TEAB with 20 mM TCEP, and 40 mM IAA were added to the 493
- PCT-Microtubes for 60 min. The proteins were digested using a mixture of trypsin 494
- 495 and Lys-C for 100 min. Then, the digestion was arrested by adding 10%
- trifluoroacetic acid (TFA). 496

#### LC-MS/MS Analysis 497

The proteome analysis was performed similar as previously described (Shen et al., 498 2020). Digested peptides were cleaned-up and labeled using TMTpro 16plex label 499 reagents (Thermo Fisher Scientific, San Jose, USA). Peptides were separated into 500 30 fractions, which were later combined into 15 fractions. Subsequently, the fractions 501 were dried, redissolved in 2% ACN/0.1% formic acid. All the samples were analyzed 502 using liquid chromatography (LC)-coupled tandem mass spectrometry (MS/MS) with 503 504 a data-dependent acquisition mode on an Orbitrap 480 (Thermo Fisher Scientific, 505 San Jose, USA). During each acquisition, peptides were analyzed using a 30 minutes-long LC gradient (from 7% to 30% buffer B). The m/z range of MS1 was 506 375-1800, with a resolution of 60,000, normalized Automatic Gain Control (AGC) 507 target of 300%, maximum ion injection time (max IT) of 50 ms, and compensation 508 voltages of -48V and -68V for FAIMS Pro™. MS/MS experiments were performed 509 with a resolution of 30,000, normalized AGC target of 200%, and 86 ms max IT for 510 511 Serum and 100 ms for PBMC. The turbo-TMT and the advanced peak determination

were enabled. 512

#### **Database Search for Proteomics Quantification** 513

The mass spectrometric data were analyzed using Proteome Discoverer (Version 514 515 2.4.0.305, Thermo Fisher Scientific) and the Homo sapiens protein database 516 downloaded from UniProtKB on 27 April 2020 (Fasta file containing 20,301 reviewed protein sequences). The database search was performed as previously described 517 (Shen et al., 2020), including Carbamidomethyl (C) as a fixed modification and 518 519 oxidation (M) as a variable modification. The false discovery rate (FDR) was set as 0.01. Data normalization was performed against the total peptide amount. Other 520 parameters followed the default setup. 521

#### **Quality Control of the Proteome Data** 522

The quality of the proteomics data was ensured at multiple levels. A pool of samples 523 labeled by TMTpro-134N was used as the control for aligning the data from different 524 batches. Also, we assessed the reproducibility of the data using technical replicates, 525

- water samples (buffer A) as blanks every four injections to avoid carry-over. 526
- 527 After removing the proteins with over 90% missing values, 6331 proteins of PBMC
- and 961 of serum underwent quality controls. We then assessed the coefficient of 528
- variation in the pooled samples (Figure S2B). Finally, the Pearson's correlation 529

- values of the technical replicates (17 PBMC samples and three serum samples) were
- used to evaluate the reproducibility of the data (Figure S2C).

# 532 Statistical Analysis of Clinical Indicators

- 533 Continuous variables were calculated by student t-test or Welch t-test, Pearson  $\chi^2$
- test or Fisher's exact test for the analysis of categorical outcomes. We calculated
- 535 Geometric Mean Titers (GMT) of the neutralizing antibody titers and the overall anti-
- 536 Spike IgG levels, using the t-test method to compare the difference. Statistical
- 537 analysis was performed by IBM SPSS Statistics 26 (Armonk, NY: IBM Corp).

# 538 Differential Expression Analysis

- 539 A set of statistical tools were used to process and analyze our proteomics data. First,
- 540 the batch effect of the serum proteome was removed using the R package combat
- 541 (https://lifeinfor.shinyapps.io/batchserver/). No other significant batch effect was
- 542 highlighted by principal component analysis (Figures S2D-E). For comparing the
- 543 protein expressions between groups, the log<sub>2</sub>(fold change) was calculated using the
- 544 mean values of each group. A two-sided unpaired Welch's t-test was performed for
- each group pair. A one-way analysis of variance (ANOVA) was performed among
  three groups at three time points. Finally, the adjusted p-values were calculated using
  the B-H correction.
- 548 DEPs were selected by imposing the B-H adjusted p-values to be less than 0.05 and
- 549 the absolute log<sub>2</sub>(fold change) larger than 0.25. Next, a soft clustering of the time
- 550 series data was performed using MFuzz (version 2.48.0). We clustered the PBMC
- and serum DEPs expression along time using default settings (Figure S6). The
- 552 single-cell RNA expression of PBMCs was derived from the Human Proteins Atlas
- 553 (HPA; Karlsson et al., 2021).

# 554 Estimation of the Immune Cell Type Fractions

- 555 CIBERSORT (https://cibersort.stanford.edu/) is an analytical tool for estimating the
- cell composition of tissues using their gene expression profiles (Newman et al.,
- 557 2015). In CIBERSORT, the relative amounts of 20 human immune cell types
- 558 (including naïve and memory B cells, seven T cell types, NK cells, plasma cells,
- 559 monocytes, etc.) were estimated in our PBMC bulk cells using the leukocyte gene
- signature matrix. In addition, vaccinated individuals were divided into seronegative
- and seropositive groups, and the fraction of each immune cell type was investigated
- and visualized with bar plots using R software (R 4.0.5).

# 563 Machine Learning

- 564 For prediction of NAbs generation on D57, we used the samples from a discovery
- 565 cohort (Cohort 1, N = 137) to optimize the model's parameters, the discovery dataset
- was randomly split into a training (80%) and a validation (20%) dataset. To establish
- the features for our machine learning models, we used a differential protein
- 568 expression analysis which returned a set of biomarkers from the PBMCs and the
- serum (Figure 2A and 5A). Proteins with a significant difference (p-value < 0.05)

between two classes and with  $|\log_2(fold change)| > 0.25$  in the training dataset were 570 included in our final feature set. Then, sparse proteins (NA rate > 50%) were 571

- removed. The missing values were imputed with the minimum of each protein. We 572
- decided on the top N best features as the final feature set for our model, as well as 573
- 574 the optimal parameters, by searching for the highest AUC in the validation dataset.
- 575 All individual models for these two tasks can achieve an AUC of 1.0 in the validation
- dataset. Finally, the results illustrated in this paper were derived from the model with 576
- the best features and parameters. The implementation of machine learning was done 577
- using Python 3.8.10 and xgboost 1.4.2 python package (Chen and Guestrin, 578
- 2016). The model was then tested using an independent test cohort (Cohort 2, N =579
- 26): the first based on PBMC biomarkers and the second on serum biomarkers. We 580 next developed a third model that was an ensemble of the two previous ones. This 581 582 third model led to an AUC of 0.87, which was higher than using PBMC or serum 583 proteins individually.
- For prediction of NAbs persistence till D180, we discarded participants from Group 0 584
- (the seronegative ones) and those without clinical indicators on D180, and the 585 586 remaining two cohorts: a training cohort (Cohort 3, N = 107) and a test cohort for the 587 validation (Cohort 4, N = 20). We optimized the models' parameters in the training and a validation dataset. Similarly, we tested in Cohort 4, and an AUC score of 0.79 588
- was obtained using only the PBMC proteins (Figure 5A). 589

#### **Functional Analyses** 590

591 Specifically, we investigated 38 PBMC DEPs and 14 serum DEPs from different immune response groups using a two-sided unpaired Welch's t-test, and 985 DEPs 592 from PBMCs and 129 DEPs from serum were evaluated using the ANOVA test, 593 biomarker proteins were also included. Several pathway analysis tools were used to 594 perform the functional analysis of our significantly DEPs. Enrichments analyses 595 based on Gene Ontology processes, KEGG pathways, Reactome gene sets, and 596 Wiki pathways were performed using the web-based platform of Metascape (Zhou et 597 al., 2019). With an ingenuine pathway analysis (Kramer et al., 2014) of the regulated 598 proteins, we identified the most significantly regulated pathways; p-values were 599 based on a right-tailed Fisher's Exact Test, and the enriched pathways' overall 600 activation/inhibition state was predicted using the z-score. A pathway's regulation 601 was significant if its p-value < 0.05. Gene Set Variation Analysis (GSVA) was 602 performed using the R package GSVA (version 3.11) (Hanzelmann et al., 2013) to 603 identify the most dysregulated pathways (Canonical pathways) between the 604 605 seronegative and the seropositive groups (B-H adjusted p-value < 0.05). The functional network images generated by Metascape were visualized with Cytoscape 606 (version 3.9.0) to generate the network of predicted associations for a specific group 607 of proteins (Otasek et al., 2019). 608

609

### 610 **References**

- 611 Ai, J., Guo, J., Zhang, H., Zhang, Y., Yang, H., Lin, K., Song, J., Fu, Z., Fan, M., Zhang, Q., et al.
- 612 (2022). Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or
- 613 heterologous booster vaccination analyzed by single-cell immune profiling. Cell Discovery 8.
- Arunachalam, P.S., Scott, M.K.D., Hagan, T., Li, C., Feng, Y., Wimmers, F., Grigoryan, L., Trisal, M.,
- Edara, V.V., Lai, L., et al. (2021). Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
- 616 Nature 596, 410-416.
- 617 Bi, X., Liu, W., Ding, X., Liang, S., Zheng, Y., Zhu, X., Quan, S., Yi, X., Xiang, N., Du, J., et al. (2021).
- Proteomic and metabolomic profiling of urine uncovers immune responses in patients withCOVID-19. Cell Rep, 110271.
- Botham, K.M., and Wheeler-Jones, C.P. (2013). Postprandial lipoproteins and the molecular
  regulation of vascular homeostasis. Prog Lipid Res 52, 446-464.
- Brannagan, T.H., 3rd, Auer-Grumbach, M., Berk, J.L., Briani, C., Bril, V., Coelho, T., Damy, T.,
- Dispenzieri, A., Drachman, B.M., Fine, N., et al. (2021). ATTR amyloidosis during the COVID-19
- 624 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis 16, 204.
- 625 C, D.A.-M., Couto, A.E.S., Campos, L.C.B., Vasconcelos, T.F., Michelon-Barbosa, J., Corsi, C.A.C.,
- 626 Mestriner, F., Petroski-Moraes, B.C., Garbellini-Diab, M.J., Couto, D.M.S., *et al.* (2021). MMP-2
- and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients.Biomed Pharmacother 142, 112067.
- 629 Chen, T.Q., and Guestrin, C. (2016). XGBoost: A Scalable Tree Boosting System. Kdd'16:
- 630 Proceedings of the 22nd Acm Sigkdd International Conference on Knowledge Discovery and631 Data Mining, 785-794.
- 632 Chen, Y., Yin, S., Tong, X., Tao, Y., Ni, J., Pan, J., Li, M., Wan, Y., Mao, M., Xiong, Y., et al. (2021).
- 633 Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an
- 634 inactivated COVID-19 vaccine. Clinical microbiology and infection : the official publication of the
   635 European Society of Clinical Microbiology and Infectious Diseases.
- 636 Costa Clemens, S.A., Weckx, L., Clemens, R., Almeida Mendes, A.V., Ramos Souza, A., Silveira,
- 637 M.B.V., da Guarda, S.N.F., de Nobrega, M.M., de Moraes Pinto, M.I., Gonzalez, I.G.S., et al. (2022).
- 638 Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two
- doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single
- 640 blind, randomised study. The Lancet.
- Davey, A., McAuley, D.F., and O'Kane, C.M. (2011). Matrix metalloproteinases in acute lung injury:
- 642 mediators of injury and drivers of repair. Eur Respir J 38, 959-970.
- de Souza, J.G., Starobinas, N., and Ibanez, O.C.M. (2021). Unknown/enigmatic functions of
- 644 extracellular ASC. Immunology 163, 377-388.
- Falsey, A.R., Frenck, R.W., Jr., Walsh, E.E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Bailey,
- R., Swanson, K.A., Xu, X., *et al.* (2021). SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose
  3. N Engl J Med 385, 1627-1629.
- 648 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., et al.
- 649 (2020). Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue
- 650 Samples Using Pressure Cycling Technology. J Proteome Res 19, 1982-1990.
- Guerra-De-Blas, P.D.C., Bobadilla-Del-Valle, M., Sada-Ovalle, I., Estrada-Garcia, I., Torres-

medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

- 652 Gonzalez, P., Lopez-Saavedra, A., Guzman-Beltran, S., Ponce-de-Leon, A., and Sifuentes-
- 653 Osornio, J. (2019). Simvastatin Enhances the Immune Response Against Mycobacterium
- 654 tuberculosis. Front Microbiol 10, 2097.
- 655 Han, X., Fiehler, R., and Broze, G.J., Jr. (2000). Characterization of the protein Z-dependent 656 protease inhibitor. Blood 96, 3049-3055.
- 657 Hanzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: gene set variation analysis for
- 658 microarray and RNA-seg data. BMC Bioinformatics 14, 7.
- 659 HPA. Human Protein Atlas, pp. https://www.proteinatlas.org/.
- 660 lizuka, Y., Cichocki, F., Sieben, A., Sforza, F., Karim, R., Coughlin, K., Isaksson Vogel, R., Gavioli, R.,
- 661 McCullar, V., Lenvik, T., et al. (2015). UNC-45A Is a Nonmuscle Myosin IIA Chaperone Required
- 662 for NK Cell Cytotoxicity via Control of Lytic Granule Secretion. J Immunol 195, 4760-4770.
- 663 Kabra, N.H., Kang, C., Hsing, L.C., Zhang, J., and Winoto, A. (2001). T cell-specific FADD-deficient
- 664 mice: FADD is required for early T cell development. Proc Natl Acad Sci U S A 98, 6307-6312.
- 665 Karlsson, M., Zhang, C., Mear, L., Zhong, W., Digre, A., Katona, B., Sjostedt, E., Butler, L., Odeberg,
- 666 J., Dusart, P., et al. (2021). A single-cell type transcriptomics map of human tissues. Sci Adv 7.
- 667 Karmaus, P.W., Shi, M., Perl, S., Biancotto, A., Candia, J., Cheung, F., Kotliarov, Y., Young, N.,
- 668 Fessler, M.B., and Consortium, C.H.I. (2019). Effects of rosuvastatin on the immune system in 669 healthy volunteers with normal serum cholesterol. JCI Insight 4.
- 670 Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in
- 671 Ingenuity Pathway Analysis. Bioinformatics 30, 523-530.
- 672 Krause, P.R., Fleming, T.R., Peto, R., Longini, I.M., Figueroa, J.P., Sterne, J.A.C., Cravioto, A., Rees,
- 673 H., Higgins, J.P.T., Boutron, I., et al. (2021). Considerations in boosting COVID-19 vaccine 674 immune responses. Lancet 398, 1377-1380.
- 675 Lee, A., Wong, S.Y., Chai, L.Y.A., Lee, S.C., Lee, M.X., Muthiah, M.D., Tay, S.H., Teo, C.B., Tan, B.K.J.,
- 676 Chan, Y.H., et al. (2022). Efficacy of covid-19 vaccines in immunocompromised patients:
- 677 systematic review and meta-analysis. BMJ 376, e068632.
- 678 Liu, J., Wang, J., Xu, J., Xia, H., Wang, Y., Zhang, C., Chen, W., Zhang, H., Liu, Q., Zhu, R., et al.
- 679 (2021). Comprehensive investigations revealed consistent pathophysiological alterations after 680 vaccination with COVID-19 vaccines. Cell Discov 7, 99.
- Meizlish, M.L., Pine, A.B., Bishai, J.D., Goshua, G., Nadelmann, E.R., Simonov, M., Chang, C.H., 681
- 682 Zhang, H., Shallow, M., Bahel, P., et al. (2021). A neutrophil activation signature predicts critical 683 illness and mortality in COVID-19. Blood advances 5, 1164-1177.
- 684 Messner, C.B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube,
- K., Vernardis, S.I., Egger, A.-S., Kreidl, M., et al. (2020). Ultra-High-Throughput Clinical 685
- 686 Proteomics Reveals Classifiers of COVID-19 Infection. Cell Systems 11, 11-24.e14.
- 687 Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and
- 688 Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat 689 Methods 12, 453-457.
- 690 Otasek, D., Morris, J.H., Boucas, J., Pico, A.R., and Demchak, B. (2019). Cytoscape Automation:
- 691 empowering workflow-based network analysis. Genome Biol 20, 185.
- 692 Sadarangani, M., Marchant, A., and Kollmann, T.R. (2021). Immunological mechanisms of
- 693 vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology 21,
- 694 475-484.

- Schroeder, H.W., Jr., and Cavacini, L. (2010). Structure and function of immunoglobulins. J Allergy 695 696 Clin Immunol 125, S41-52,
- 697 Serrador, J.M., Nieto, M., Alonso-Lebrero, J.L., del Pozo, M.A., Calvo, J., Furthmayr, H., Schwartz-
- 698 Albiez, R., Lozano, F., Gonzalez-Amaro, R., Sanchez-Mateos, P., et al. (1998). CD43 interacts with
- 699 moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell
- 700 contacts. Blood 91, 4632-4644.
- 701 Sette, A., and Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184,
- 702 861-880.
- 703 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Ouan, S., Zhang, F., Sun, R., Oian, L., et al. (2020).
- 704 Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell 182, 59-72 e15.
- 705 Sternlicht, M.D., and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior.
- 706 Annu Rev Cell Dev Biol 17, 463-516.
- 707 Ueland, T., Holter, J.C., Holten, A.R., Muller, K.E., Lind, A., Bekken, G.K., Dudman, S., Aukrust, P.,
- 708 Dyrhol-Riise, A.M., and Heggelund, L. (2020). Distinct and early increase in circulating MMP-9 in
- 709 COVID-19 patients with respiratory failure. J Infect 81, e41-e43.
- 710 van der Graaf, R., Browne, J.L., and Baidjoe, A.Y. (2022). Vaccine equity: past, present and future. 711 Cell Reports Medicine.
- 712 Wang, Y., Ning, X., Gao, P., Wu, S., Sha, M., Lv, M., Zhou, X., Gao, J., Fang, R., Meng, G., et al.
- 713 (2017). Inflammasome Activation Triggers Caspase -1-Mediated Cleavage of cGAS to Regulate
- 714 Responses to DNA Virus Infection. Immunity 46, 393-404.
- 715 Wang, Y., Wang, X., Luu, L.D.W., Chen, S., Jin, F., Wang, S., Huang, X., Wang, L., Zhou, X., Chen, X.,
- 716 et al. (2022). Proteomic and Metabolomic Signatures Associated With the Immune Response in
- 717 Healthy Individuals Immunized With an Inactivated SARS-CoV-2 Vaccine. Front Immunol 13, 718 848961.
- 719 WHO (2022-10-25). WHO Coronavirus (COVID-19) Dashboard.
- 720 Xue, J.-b., Lai, D.-y., Jiang, H.-w., Qi, H., Guo, S.-j., Zhu, Y.-s., Xu, H., Zhou, J., and Tao, S.-c.
- 721 (2022). Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated 722 virus vaccine against the Omicron variant. Cell Discovery 8.
- 723 Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al.
- 724 (2021). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a
- 725 two-dose schedule, in healthy adults: interim results from two single-centre, double-blind,
- 726 randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis.
- 727 Zhang, H., Hu, Y., Jiang, Z., Shi, N., Lin, H., Liu, Y., Wang, H., Feng, Y., Meng, X., Zhang, S., et al.
- 728 (2021). Single-Cell Sequencing and Immune Function Assays of Peripheral Blood Samples
- 729 Demonstrate Positive Responses of an Inactivated SARS-CoV-2 Vaccine.
- 730 Zhao, X., Li, D., Ruan, W., Chen, Z., Zhang, R., Zheng, A., Qiao, S., Zheng, X., Zhao, Y., Dai, L., et al.
- 731 (2022). Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. N Engl J 732 Med.
- 733 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and
- 734 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of
- 735 systems-level datasets. Nat Commun 10, 1523.

# 736 Tables

- Table 1. Clinical metadata of the subjects for Group 0 and Group 1+2.
- Table 2. Clinical metadata of the subjects for Group 3 and Group 4.

	Discovery	Test cohort		Disc	overy cohort		т	est cohort	
Characteristics	cohort (Cohort 1, N = 137)	(Cohort 2, N = 26)	р	Group 0 (N = 14)	Group 1+2 (N = 123)	р	Group 0 (N = 5)	Group 1+2 (N = 21)	p
Age (years)	38.839 (11.806)	41.615 (8.782)	0.171	44.643 (12.258)	38.179 (11.622)	0.052	51.800 (5.495)	39.191 (7.633)	0.002
Sex (male/female)	43/94	16/10	0.141	6/8	37/86	0.329	5/0	11/10	0.123
Body mass index (kg/m <sup>2</sup> )	24.026 (3.770)	25.314 (3.138)	0.104	26.002 (4.465)	23.801 (3.636)	0.064	26.208 (4.955)	25.097 (2.676)	0.650
Total bilirubin (µmol/L)	19.883 (6.726)	19.285 (5.663)	0.671	19.650 (5.490)	19.909 (6.871)	0.892	20.080 (6.058)	19.095 (5.706)	0.734
Albumin (g/L)	48.457 (2.302)	47.015 (2.706)	0.005	47.979 (2.555)	48.511 (2.277)	0.414	45.820 (1.587)	47.300 (2.865)	0.281
Alanine aminotransferase (U/L)	20.479 (18.397)	20.704 (10.932)	0.952	17.607 (8.737)	20.806 (19.186)	0.540	19.840 (12.213)	20.910 (10.923)	0.849
Aspartate aminotransferase (U/L)	20.410 (9.150)	22.054 (5.075)	0.375	18.693 (5.496)	20.606 (9.473)	0.461	23.620 (6.460)	21.681 (4.806)	0.454
Alkaline phosphatase (U/L)	66.730 (20.253)	69.462 (17.775)	0.522	67.929 (19.828)	66.594 (20.376)	0.816	72.200 (12.696)	68.810 (18.983)	0.710
γ-glutamyl transpeptidase (U/L)	24.854 (21.930)	22.692 (12.142)	0.626	19.714 (10.542)	25.439 (22.823)	0.357	21.600 (7.956)	22.952 (13.086)	0.828
LDL-cholesterol (mmol/L)	3.118 (0.779)	3.106 (0.883)	0.941	2.796 (0.705)	3.155 (0.782)	0.102	3.264 (0.108)	3.068 (0.982)	0.665
HDL-cholesterol (mmol/L)	1.372 (0.326)	1.220 (0.268)	0.026	1.266 (0.182)	1.384 (0.337)	0.092	1.284 (0.163)	1.205 (0.288)	0.563
Total cholesterol (mmol/L)	4.965 (0.966)	4.860 (0.983)	0.611	4.557 (0.928)	5.012 (0.963)	0.103	4.984 (0.172)	4.830 (1.094)	0.760
Triglyceride (mmol/L)	1.017 (0.566)	1.174 (0.645)	0.207	1.089 (0.603)	1.009 (0.564)	0.618	0.962 (0.263)	1.225 (0.701)	0.424
Glucose (mmol/L)	4.146 (1.141)	3.502 (0.826)	0.007	4.210 (1.096)	4.138 (1.150)	0.825	3.398 (1.092)	3.526 (0.782)	0.762
Creatinine (µmol/L)	60.307 (29.087)	67.923 (13.702)	0.194	57.786 (17.375)	60.594 (30.169)	0.607	75.800 (13.046)	66.048 (13.47)	0.157
Uric Acid (µmol/L)	307.839 (95.341)	343.385 (83.196)	0.078	309.286 (52.889)	307.675 (99.170)	0.952	384.400 (75.075)	333.619 (83.690)	0.227
CRP (mg/L)	1.407 (3.782)	1.206 (1.341)	0.790	1.180 (1.460)	1.442 (3.979)	0.808	1.624 (1.984)	1.235 (1.239)	0.579

# 739Table 1. Clinical metadata of the subjects for Group 0 and Group 1+2.

Leukocytes (10 <sup>9</sup> /L)	6.203 (1.453)	6.692 (1.517)	0.120	2.164 (0.674)	2.063 (0.591)	0.594	6.320 (1.659)	6.781 (1.511)	0.552
Platelets (10 <sup>9</sup> /L)	247.796 (57.838)	271.500 (59.567)	0.058	245.143 (62.954)	248.098 (57.496)	0.857	227.200 (53.742)	282.048 (57.010)	0.063
Red blood cells (10 <sup>9</sup> /L)	6.203 (1.453)	6.692 (1.517)	0.120	4.742 (0.452)	4.732 (0.630)	0.953	5.320 (0.409)	5.043 (0.605)	0.344
Lymphocytes (10 <sup>9</sup> /L)	2.074 (0.598)	2.323 (0.513)	0.048	2.164 (0.674)	2.063 (0.591)	0.552	2.060 (0.541)	2.386 (0.499)	0.209
hemoglobin (g/L)	140.985 (19.497)	150.039 (20.166)	0.032	138.143 (22.408)	141.309 (19.215)	0.567	160.800 (13.608)	147.476 (20.868)	0.190
Comorbidities, N (%)									
Hypertension	13 (9)	6 (23)	0.005	1 (7)	12 (10)	0.092	2 (40)	4 (19)	0.558
T2DM	5 (4)	0 (0)	>0.999	1 (7)	4 (3)	0.426	0 (0)	0 (0)	>0.999
MAFLD	37 (27)	13 (50)	0.020	7 (50)	30 (24)	0.005	2 (40)	11 (52)	>0.999
Seroconversion of neutra	lizing antibody to liv	ve SARS-CoV-2, I	N (%)						
Day 28	30 (22)	2 (7)	0.112	0 (0)	30 (25)	0.040	0 (0)	2 (10)	>0.999
Day 57	123 (90)	21 (81)	0.189	0 (0)	123 (100)	>0.999	0 (0)	21 (100)	<0.001
Day 180	30 (25) <sup>a</sup>	12 (48) <sup>b</sup>	0.021	0 (0) <sup>c</sup>	30 (28) <sup>d</sup>	>0.999	0 (0) <sup>e</sup>	12 (60) <sup>f</sup>	0.043
GMT of neutralizing antib	ody to live SARS-Co	oV-2 (AU/mL)							
Day 28	8.523 (5.368)	6.789 (2.781)	0.018	4.817 (1.185)	8.945 (5.497)	<0.001	4.658 (1.379)	7.296 (2.807)	.055
Day 57	27.372 (28.155)	23.309 (19.138)	0.482	7.746 (1.293)	29.606 (28.884)	<0.001	7.948 (1.64)	26.967 (19.602)	.043
Day 180	8.627 (4.315)	10.795 (4.325)	0.024	6.055 (1.976)	8.94 (4.422)	<0.001	6.842 (0.343)	11.784 (4.297)	<0.001

740 Data are shown as mean values (standard deviation within parentheses) and N (%). Pearson  $\chi^2$  test or Fisher's exact test were used to analyze the

categorical outcomes and student t-test or Welch t-test for continuous outcomes. Hypertension was defined as systolic blood pressure ≥140 or

742 diastolic blood pressure  $\geq$  90 mmHg. T2DM: Type 2 diabetes mellitus, which was defined as fasting glucose  $\geq$  7.0 mmol/L. MALFD: metabolic

associated fatty liver disease. Superscripts a, b, c, d, e, and f: subjects left in each group were 120, 25, 13, 107, 5, and 20, respectively. Group 0, the

seronegative group, included the participants that were seronegative on D28 and D57. Groups 1+2 were all the seropositive participants on D57.

	Discovery	Test cohort		Discovery coho	rt		Test cohort		
Characteristics	cohort (Cohort 3, N = 107)	(Cohort 4, N = 20)	р	Group 3 (N = 77)	Group 4 (N = 30)	р	Group 3 (N = 8)	Group 4 (N = 12)	р
Age (years)	40.019 (10.814)	39.950 (6.970)	0.971	40.130 (10.598)	39.733 (11.531)	0.866	40.625 (6.278)	39.500 (7.634)	0.734
Sex (male/female)	32/75	10/10	0.023	20/57	12/18	0.155	2/6	8/4	0.170
Body mass index (kg/m²)	23.965 (3.746)	25.260 (2.638)	0.142	23.879 (3.660)	24.186 (4.014)	0.705	26.738 (1.701)	24.275 (2.745)	0.037
Total bilirubin (µmol/L)	20.114 (7.080)	18.735 (5.604)	0.412	20.705 (6.615)	18.597 (8.075)	0.167	20.913 (6.399)	17.283 (4.736)	0.161
Albumin (g/L)	48.492 (2.245)	47.175 (2.88)	0.023	48.239 (2.191)	49.140 (2.289)	0.062	46.200 (2.183)	47.825 (3.184)	0.226
Alanine aminotransferase (U/L)	21.114 (19.713)	21.310 (11.048)	0.966	18.468 (16.533)	27.907 (25.255)	0.066	19.350 (12.294)	22.617 (10.487)	0.532
Aspartate aminotransferase (U/L)	20.425 (9.418)	21.555 (4.895)	0.602	19.136 (7.126)	23.733 (13.243)	0.08	20.738 (4.525)	22.100 (5.248)	0.556
Alkaline phosphatase (U/L)	66.720 (21.280)	<b>69.000 (19.456</b> )	0.657	66.065 (22.940)	68.400 (16.492)	0.612	59.875 (15.524)	75.083 (19.988)	0.087
γ-glutamyl transpeptidase (U/L)	26.178 (23.377)	23.3 (13.326)	0.595	24.208 (19.513)	31.233 (31.030)	0.164	18.375 (8.123)	26.583 (15.341)	0.184
LDL-cholesterol (mmol/L)	3.160 (0.800)	3.076 (1.007)	0.680	3.097 (0.769)	3.320 (0.867)	0.196	2.605 (0.655)	3.389 (1.100)	0.088
HDL-cholesterol (mmol/L)	1.370 (0.337)	1.179 (0.27)	0.018	1.406 (0.353)	1.278 (0.276)	0.076	1.188 (0.332)	1.173 (0.235)	0.912
Total cholesterol (mmol/L)	<b>4.996 (0.935</b> )	4.821 (1.122)	0.458	4.907 (0.910)	5.223 (0.973)	0.116	4.316 (0.698)	5.157 (1.247)	0.102
Triglyceride (mmol/L)	1.025 (0.596)	1.245 (0.713)	0.145	0.888 (0.451)	1.375 (0.768)	0.002	1.154 (0.657)	1.305 (0.771)	0.655
Glucose (mmol/L)	4.181 (1.222)	3.593 (0.738)	0.040	4.229 (1.275)	4.060 (1.082)	0.524	3.405 (0.708)	3.718 (0.762)	0.367
Creatinine (µmol/L)	60.009 (31.812)	65.55 (13.621)	0.446	59.610 (37.004)	61.033 (10.440)	0.836	63.000 (10.637)	67.250 (15.51)	0.509
Uric Acid (µmol/L)	301.122 (100.483)	331.650 (85.363)	0.205	288.299 (93.366)	334.033 (111.819)	0.034	349.000 (91.377)	320.083 (83.115)	0.473

# 745 **Table 2. Clinical metadata of the subjects for Group 3 and Group 4.**

22 / 28

CDD(mat/l)	1 224 (2 520)	1 126 (1 200)	0.070	4 070 (0 004)	4 400 (4 454)	0 704	4 004 (0 007)	4 470 (4 074)	0.004
CRP (mg/L)	1.224 (2.529)	1.136 (1.209)	0.879	1.270 (2.904)	1.106 (1.151)	0.764	1.084 (0.997)	1.170 (1.374)	0.881
Leukocytes (10 <sup>9</sup> /L)	6.173 (1.516)	6.815 (1.542)	0.085	6.012 (1.424)	6.587 (1.685)	0.078	6.500 (1.009)	7.025 (1.828)	0.471
Platelets (10 <sup>9</sup> /L)	245.738 (60.240)	287.100 (53.450)	0.005	242.351 (60.909)	254.433 (58.591)	0.354	276.500 (53.407)	294.167 (54.621)	0.484
Red blood cells (10 <sup>9</sup> /L)	<b>4.719 (0.654</b> )	5.020 (0.611)	0.059	4.631 (0.679)	4.943 (0.533)	0.026	4.675 (0.534)	5.25 0(0.565)	0.035
Lymphocytes (10 <sup>9</sup> /L)	2.026 (0.577)	2.395 (0.510)	0.009	1.949 (0.544)	2.223 (0.622)	0.027	2.188 (0.491)	2.533 (0.494)	0.142
hemoglobin (g/L)	141.037 (20.188)	146.600 (21.01)	0.263	138.558 (21.516)	147.400 (14.776)	0.041	143.375 (14.956)	148.750 (24.647)	0.589
Comorbidity, N (%)									
Hypertension	12 (12)	4 (20)	0.280	8 (11)	4 (14)	0.736	0 (0)	4 (34)	0.094
T2DM	4 (4)	0 (0)	>0.999	3 (4)	1 (4)	>0.999	0 (0)	0 (0)	>0.999
MAFLD	30 (28)	11 (55)	0.018	17 (22)	13 (43)	0.028	5 (63)	6 (50)	0.670
Seroconversion of neutralized	zing antibody to li	ve SARS-CoV-2, N	(%)						
Day 28	26 (25)	2 (10)	0.240	16 (21)	10 (34)	0.174	0 (0)	2 (17)	0.475
Day 57	107 (100)	20 (100)	>0.999	77 (100)	30 (100)	>0.999	8 (100)	12 (100)	>0.999
Day 180	30 (29)	11 (55)	0.018	0 (0)	30 (100)	<0.001	0 (0)	12 (100)	<0.001
GMT of neutralizing antiboo	dy to live SARS-Co	oV-2 (AU/mL)							
Day 28	9.033 (5.837)	7.41 (2.83)	0.023	8.034 (4.35)	11.596 (8.092)	0.028	6.0563 (1.07254)	8.3125 (3.29792)	0.045
Day 57	29.925 (30.425)	27.133 (20.096)	0.694	24.596 (27.2)	43.603 (34.288)	0.009	15.695 (6.17745)	34.7583 (22.6869)	0.034
Day 180	8.94 (4.422)	11.784 (4.297)	0.009	6.905 (1.641)	14.162 (5.021)	<0.001	8.475 (0.68498)	13.9892 (4.28151)	0.001

746 Data are shown as mean values (standard deviation in parentheses). Pearson  $\chi^2$  test or Fisher's exact test were used to analyze the categorical

747 outcomes and student t-test or Welch t-test for continuous outcomes. Hypertension was defined as systolic blood pressure ≥140 or diastolic blood

pressure  $\geq$  90 mmHg. T2DM: Type 2 diabetes mellitus, which was defined as fasting glucose  $\geq$  7.0 mmol/L. MALFD: metabolic associated fatty liver

disease. Group 3: the group that became seronegative before D180; Group 4: the group that was seropositive at least until D180.

### 750 Figure legends

Figure 1. Study design and overview of clinical indicators. (A) Study design of 751 the TMT labeling-based quantitative proteomics analysis of the PBMCs and sera 752 samples. Vaccination recipients were vaccinated with two doses of 500 µl 753 CoronaVac<sup>®</sup>, the first at D0 and the second at D28. Blood samples and PBMCs were 754 755 collected at D0 (before vaccination), D28, and D57. Participants were divided into 756 four groups based on the xenoreactivity of their NAbs on D28 and D57: Group 0, the seronegative group, included the participants that were seronegative on D28 and 757 758 D57; Group 1, the late seropositive group, included the participants that were seronegative on Day 28 but seropositive on D57: Group 2, the early seropositive 759 group, included the participants that were seropositive on D28 and D57. Groups 1 760 and 2 were combined into Group 1+2 to bring together all the seropositive 761 participants. Group 1+2 was then divided into Group 3 (seronegative participants on 762 D180) and Group 4 (seropositive participants on D180). (B-C) Antibody titers of 763 neutralizing antibodies (B) and Spike-specific IgG (C) to live SARS-CoV-2 at different 764 765 time points after vaccination. The horizontal line represents the threshold of specific response. The bars represent the median and IQR values of titers. Sample 766 comparisons were tested by student t-test or Welch t-test. \* Represents p < 0.05, \*\* 767 represents p < 0.01, \*\*\* represents p < 0.001. 768

### **Figure 2. Machine learning-based prediction of individuals' seronegative or**

seropositive status based on their PBMCs and serum proteins before 770 vaccination. (A) Our machine learning-based predictor was based on PBMC, serum, 771 and both types of proteins. We used the samples from a discovery cohort (Cohort 1, 772 N = 137) to optimize the model's parameters, the discovery dataset was randomly 773 split into a training (80%) and a validation (20%) dataset. The model was then tested 774 775 using a test cohort (Cohort 2, N = 26): the first based on PBMC biomarkers and the second on serum biomarkers. We next developed a third model that was an 776 ensemble of the two previous ones. This third model led to an AUC of 0.87, which 777 was higher than using PBMC or serum proteins individually. (B) The SHAP values of 778 the five PBMC proteins were prioritized using the machine learning model. (C) The 779 SHAP values of the seven serum proteins were prioritized using the machine 780 learning model. (D) Boxplots of the selected biomarker proteins from the PBMC 781 782 samples. (E) Boxplots of the selected biomarker proteins from the serum samples. 783 Asterisks in (D) and (E) indicate the statistical significance based on the unpaired two-sided Welch's t-test. Specifically, the p-values are: \*, < 0.05; \*\*, < 0.01; \*\*\*, < 784 0.001. Group 0: the seronegative group; Group 1+2: the seropositive group. 785

# Figure 3. Comparison of the immune responses in the seropositive and the

787 seronegative groups using the PBMCs proteome. (A) Identification of NAb status-

- associated proteins in PBMC using volcano plot analysis on D0, D28, and D57 (two sided unpaired Welch's t-test). The log<sub>10</sub>(B-H adjusted p-value) is plotted as a
- sided unpaired Welch's t-test). The  $log_{10}$ (B-H adjusted p-value) is plotted as a function of the  $log_2$ (fold change) between seropositive and seronegative samples (B-

H adjusted p-value < 0.05,  $|\log_2(\text{fold change})| > 0.25$ ). (B) Heatmap of the proteins 791 that were significantly regulated in (A). The expression of each protein is shown for 792 both immune response groups and at D0, D28, and D57. (C) Heatmap of the most 793 significantly differentially enriched pathways between the seropositive and the 794 795 seronegative groups generated using GSVA (B-H adjusted p-value < 0.05,  $llog_2$  (fold 796 change) > 0.25). (D) Barplot visualizing the inferred proportions of 20 immune cell types. The average proportions of the 20 immune cell types were derived from the 797 seronegative (Group 0) and the seropositive (Group 1+2) groups. (E) Barplots 798 visualizing the average proportions (mean ± standard error of mean) of B cells, T 799 cells, and several innate immune cells, in the seronegative (Group 0) and 800 801 seropositive (Group 1+2) groups at three time points. Asterisks in (D) and (E) indicate the statistical significance based on the Mann-Whitney rank test. P-value: \*, < 0.05; 802 803 \*\*, < 0.01; \*\*\*, < 0.001.

#### Figure 4. Comparison of the immune responses in the seropositive and the 804

805 seronegative groups using the serum proteome. (A) Identification of NAb status-806 associated proteins in serum using volcano plot analysis on D0, D28, and D57 by the two-sided unpaired Welch's t-test. The B-H adjusted p-values are plotted as functions 807 of the log<sub>2</sub>(fold change) of the mean values between the seropositive and the 808 seronegative samples (B-H adjusted p-value < 0.05,  $|\log_2(fold change)| > 0.25$ ). (B) 809 Heatmap of the proteins that were significantly regulated in (A). The expression of 810 each protein is shown for both immune response groups and at D0, D28, and D57. 811 812 (C) The most significantly enriched networks generated using significantly dysregulated proteins from the serum proteome. Proteins involved in plasma 813 lipoprotein remodeling and neutrophil degranulation are shown with their expression 814 levels in the seropositive and the seronegative groups at three time points. The cutoff 815 of the dysregulated proteins was set at p-value < 0.05 and  $|\log_2(fold change)| > 0.25$ . 816 The proteins highlighted with a red \* had B-H adjusted p-values < 0.05, while those 817 818 with a black \* were selected from our optimized machine learning models. Group 0: the seronegative group; Group 1+2: the seropositive group. 819

Figure 5. Proteomics of seropositive and seronegative individuals 180 days 820

after CoronaVac<sup>®</sup> vaccination. (A) Workflow for generating a model to predict the 821 antibody persistence till D180. We discarded participants from Group 0 (the 822 823 seronegative ones) and those without clinical indicators on D180, the remaining two 824 cohorts: a training cohort (Cohort 3, N = 107) and a test cohort for the validation (Cohort 4, N = 20). (B) SHAP values of the machine learning classifier trained with 825 selected PBMC proteins. (C) Expression of the selected proteins from the PBMC 826 samples. The asterisks indicate the statistical significance based on the unpaired 827 two-sided Welch's t-test. P-value: \*, < 0.05; \*\*, < 0.01; \*\*\*, < 0.001. Group 3 (N = 828 107): the seronegative group on D180; Group 4 (N = 20): the persistently 829 seropositive group. (D) Relative expression of the proteins selected for our model in 830 the different cell type clusters of PBMCs (data from the Human Proteins Atlas(HPA; 831

Karlsson et al., 2021)). 832

# 833 Figure 6. Functional and network analyses of the seropositive and

834 seronegative groups' immune responses: a comparison between PBMC and

serum data. (A) Chord diagrams of the most enriched pathways based on the 835 significantly dysregulated proteins and the potential biomarker proteins. (B) Network 836 837 analysis of the most significantly enriched pathways (with their p-values) based on the DEPs and the potential biomarker proteins. (C) Key PBMC and serum proteins 838 characterized in seronegative and seropositive recipients. Proteins involved in the 839 humoral immune response, neutrophil degranulation, network maps of SARS-CoV-2 840 signaling pathways, and regulation of lymphocyte migration are shown in this network 841 with their corresponding expression levels in the seronegative and the seropositive 842 843 groups. Group 0: the seronegative group; Group 1+2: the seropositive group; Group 3: the group that became seronegative before D180; Group 4: the group that was 844 845 seropositive at least until D180.

846

Figure S1. Factors associated with seropositivity of neutralizing antibodies at
D57 and D180, respectively. (A) Multivariable logistic regression analysis was used
to investigate factors associated with the generation of NAbs at D57 after adjusting
sex, BMI and diastolic bold pressure. (B) Multivariable logistic regression analysis
was used to investigate factors associated with the persistence of NAbs at D180 after
adjusting leukocytes, monocytes, RBC, lymphocytes, hemoglobin, LDL, HDL, TG,
ALT, and AST.

854 Figure S2. Quality controls of the proteomics data. (A) Study design of our TMTlabeling-based quantitative proteomics analysis of PBMCs and sera samples. 855 Together, PBMCs and serum generated 528 peptide samples, including 33 pooled 856 controls, distributed into 33 batches and analyzed using TMTpro 16-plex labeling 857 based proteomics. (B) The proteomics data's coefficients of variation were calculated 858 using the abundance of the quantified proteins in the 33 pooled controls of the 33 859 860 batches. Also, they were computed after removing the outliers. (C) Quality control of the technical replicates based on the Pearson correlation coefficients. (D-E) PCA 861 analyses were performed on all the proteomics data derived from the PBMC (D) and 862 serum samples (E), for three immune response groups on D57 (Group 0, Group 1, 863 and Group 2) and two immune response groups on D180 (Group 3 and Group 4). 864 Group 1: the late seropositive group; Group 2: the early seropositive group. 865

Figure S3. Machine learning-based prediction of Group 1 (being negative at

867 **D28** and then converting) and Group 0 (being negative at D28 and never

converting) before vaccination. (A) Our machine learning-based predictor was 868 based on PBMC, serum, and both types of proteins. We used the samples from a 869 discovery cohort (Cohort 1, N = 137) to optimize the model's parameters. The model 870 was then tested using a test cohort (Cohort 2, N = 26): the first based on PBMC 871 biomarkers and the second on serum biomarkers. We next developed a third model 872 that was an ensemble of the two previous ones. This third model led to an AUC of 873 0.853, which was higher than using PBMC or serum proteins individually. (B) The 874 875 SHAP values of the five PBMC proteins were prioritized using the machine learning

All rights reserved. No reuse allowed without permission.

model. (C) The SHAP values of the five serum proteins were prioritized using the
machine learning model. Identification of NAb status-associated proteins in PBMC
(D) and serum (E) using volcano plot analysis on D0, D28, and D57 (two-sided
unpaired Welch's t-test). The log10 (B-H adjusted p-value) is plotted as a function of
the log2(fold change) between Group 1 and Group 0 samples (B-H adjusted p-value
< 0.05, |log2(fold change)| > 0.25).

Figure S4. Immune response and pathway analyses using the PBMC data. (A) 882 883 Heatmap of 985 proteins selected using the ANOVA test. Each protein is compared among the three immune response groups (Group 0, 1, and 2) on D0, D28, and D57 884 (p-value < 0.05). Group 0: the seronegative group; Group 1: the late seropositive 885 group; Group 2: the early seropositive group. (B-D) Pathways' enrichment based on 886 the proteins selected using the ANOVA test to compare the three immune response 887 groups on D0 (B), D28 (C), and D57 (D) using Metascape (log<sub>10</sub> p-value). (E) 888 Barplots visualizing the estimated proportions of 20 immune cell types in each PBMC 889 890 sample. Each column represents a sample; the colors indicate the inferred immune 891 cell components. (F) Average proportions of 20 immune cell types, in Group 0, Group 1, and Group 2, at three time points. The asterisks indicate the statistical significance 892 based on the Kruskal-Wallis test. P-value: \*, < 0.05; \*\*, < 0.01; \*\*\*, < 0.001. (G) 893 Barplots visualizing the estimated proportions of 20 immune cell types, in Group 0, 894 Group 1, and Group 2, at three time points. Different colors indicate the predicted 895 composition of immune cell types. 896


**Figure S5. Immune response and pathway analysis using the serum data. (A)** 

Heatmap of 129 proteins selected using the ANOVA test. Each protein is compared
between the three immune response groups (Group 0, 1, and 2) on D0, D28, and
D57 (P-value < 0.05). Group 0: the seronegative group; Group 1: the late</li>
seropositive group; Group 2: the early seropositive group. (B) Pathways' enrichment
based on the proteins selected in (A) using Metascape. (C-D) Comparison among
three immune response groups (Group 0, 1, and 2) of the canonical pathways of
proteins in (A) by IPA (Kramer et al., 2014).

Figure S6. Immune response and pathway analysis using the PBMC and the 905 serum data. (A-B) Pathways' enrichment analysis of selected PBMC proteins. 906 907 Specifically, 6331 PBMC proteins and 961 serum proteins were grouped into 12 discrete clusters using mFuzz, respectively. This analysis included all the proteins 908 from the PBMC dataset that steadily increased (A) or decreased (B) over time. And 909 the serum dataset that steadily increased (C) or decreased (D) over time. The 20 910 most significantly enriched pathways involving these DEPs were analyzed using 911 Metascape. 912

Figure S7. Immune response and network analysis of the seropositive groups:
 comparison between PBMC and serum data. The most significantly dysregulated
 proteins identified using mFuzz from the following groups are here compared: (A)
 upregulated in both PBMC and serum, (B) downregulated in both PBMC and serum,

- (C) upregulated in PBMC and downregulated in serum, and (D) downregulated in 917
- PBMC and upregulated in serum. The Venn diagrams show the overlaps between 918
- the PBMC (blue) and the serum proteins (red). Pathways and heatmaps were 919
- generated from the overlapping proteins from each pair. (E) The most significantly 920
- 921 enriched networks generated using the DEPs from (A-D). The proteins involved in
- 922 the complement system, including platelet degranulation, neutrophil degranulation,
- and protein-lipid complex remodeling. 923




\*Group 0, the seronegative group, participants who were seronegative of neutralizing antibodies (NAb) on D28 and D57.


Group 1, the late seropositive group, represents participants who were seronegative for NAb on Day 28 but were seropositive on D57.


Group 2, the early seropositive group, represents participants who were seropositive for NAb on D28 and D57.

Group 1+2, the seropositive group, Group 1 and Group 2.

Group 3, the seronegative group on D180. Group 4, the persistently seropositive group, seropositive on D180.














Figure 3 medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.









ı.

Figure S1

### А


### Seropositive of NAb titers at D57

### Univariable analysis

	pvalue	Odd ratio (95%CI)	1
Age	0.005	0.930(0.884-0.979)	
Sex (vs male)	0.042	0.364(0.137-0.963)	
BMI	0.027	0.878(0.782-0.985)	-
Diastolic Blood Pressure	0.030	0.951(0.909-0.995)	
Systolic Blood Pressure	0.093	0.970(0.937-1.005)	
NAb titers at day 28	< 0.001	3.173(1.755-5.737)	
Leukocytes	0.757	0.950(0.686-1.315)	H
Monocytes	0.370	5.804(0.124-271.388)	I I I I I I I I I I I I I I I I I I I
RBC	0.428	0.698(0.287-1.698)	<b>⊢_</b> ∎'1
Lymphocytes	0.854	0.927(0.413-2.081)	<b>⊢</b>
Plateles	0.377	1.004(0.996-1.012)	
Neutrophils	0.652	0.908(0.596-1.383)	⊢■
Hemoglobin	0.693	0.995(0.969-1.021)	
UA	0.444	0.998(0.993-1.003)	
GGT	0.340	1.017(0.983-1.052)	•
TBIL	0.986	1.001(0.930-1.077)	•
LDL	0.248	1.457(0.769-2.760)	⊧⊥ <mark>∎</mark> _⊣
HDL	0.267	2.542(0.489-13.217)	<b>⊢</b> +− <b>∎</b> −−−−−1
ТС	0.180	1.453(0.841-2.509)	h <b>r≡</b> -1
TG	0.914	0.956(0.424-2.157)	<b>⊢</b> - <b>₩</b> 1
Glucose	0.847	1.047(0.655-1.674)	⊢ <b>≓</b> ⊣
IR	0.262	0.896(0.741-1.085)	
Alb	0.119	1.179(0.958-1.449)	<b>*</b>
CRP	0.922	1.007(0.868-1.169)	· · · · · · · · · · · · · · · · · · ·
Cr	0.865	0.999(0.983-1.014)	
ALT	0.538	1.011(0.977-1.046)	
AST	0.713	1.011(0.952-1.074)	
Drug(vs without drug)	0.688	0.729(0.156-3.400)	<b>⊢</b>
MAFLD(vs non-MAFLD)	0.099	2.261(0.857-5.968)	⊦ <mark>′ ∎</mark>
Hypertension(vs non-hypertension)	0.553	1.500(0.393-5.718)	
T2DM (vs non-T2DM)	0.562	1.944(0.206-18.367)	<b>├</b> {

### Mulvariable analysis

Age	0.136	0.95
Sex (vs male)	0.992	0.99
BMI	0.053	0.85
Diastolic Blood Pressure	0.467	0.97
NAb titers at day 28	<0.001	3.07



64 256

16 4


Odd ratio

0.0625


# В


### Seropositive of NAb titers at D180


Univariable analysis			
Univariable analysis	pvalue	Odd ratio (95%CI)	1
Age	0.340	0.984(0.950-1.018)	
Sex (vs male)	0.061	2.017(0.967-4.208)	1 [ <b>∎</b> 1
BMI	0.699	0.981(0.890-1.081)	<b>•</b>
Diastolic Blood Press			±
Systolic Blood Pressu NAb titers at day 28	ire 0.209 0.003	1.018(0.990-1.046) 1.121(1.041-1.207)	<b>1</b>
NAb titers at day 57	0.002	1.030(1.011-1.049)	i i i i i i i i i i i i i i i i i i i
Leukocytes	0.028	1.334(1.032-1.725)	<b>⊢</b> ∎-1
Monocytes	0.043	16.744(1.100-254.957)	ı <del>l – – – – –</del> – – – – – – – – – – – – – –
RBC	0.001	3.425(1.618-7.250)	
Lymphocytes Platelets	0.003 0.060	2.748(1.394-5.416) 1.006(1.000-1.013)	
Neutrophils	0.390	1.150(0.836-1.580)	
Hemoglobin	0.029	1.025(1.002-1.048)	
UA	0.087	1.003(1.000-1.007)	
GGT	0.089	1.014(0.998-1.031)	
TBIL	0.062	0.943(0.888-1.003)	
LDL	0.047	1.593(1.007-2.522)	<b>⊢</b> ∎-1
HDL	0.041	0.267(0.075-0.950)	⊢ <b></b> /
TC	0.036	1.525(1.028-2.261)	<b>⊢</b> ∎-1
TG	0.001	3.010(1.603-5.650)	
Glucose IR	0.449 0.240	0.864(0.592-1.261) 1.115(0.930-1.336)	H H
Alb	0.240	1.156(0.993-1.346)	
CRP	0.846	0.983(0.828-1.168)	<b>_</b>
Cr	0.610	1.003(0.991-1.015)	
ALT	0.025	1.024(1.003-1.045)	
AST	0.021	1.051(1.007-1.097)	
Drug(vs without drug)		0.422(0.166-1.070)	⊢— <b>∎</b> —j
MAFLD(vs non-MAFL		0.521(0.249-1.092)	
Hypertension(vs non-hype		0.508(0.188-1.370) 1.657(0.180-15.273)	
T2DM (vs non-T2DM)	) 0.656	1.037(0.100-13.273)	
		0	0625 1 4 16 64 256
		0.	Odd ratio
			Odd Tallo
Mulvariable analysis			
	pvalue	Odd ratio (95%CI)	1
NAb titers at day 28	0.043	1.096(1.003-1.198)	<b>T</b>
NAb titers at day 57	0.043	1.021(1.001-1.041)	<b>-</b>
Leukocytes	0.422	0.836(0.540-1.295)	<b>T</b>
Monocytes	0.241	3.551(0.426-29.587)	-
RBC	0.123	3.260(0.727-14.613)	•
Lymphocytes	0.085	2.427(0.885-6.657)	÷
Hemoglobin	0.642	0.990(0.949-1.032)	÷
LDL	0.364 0	.000(0.000-1.276E+37)	1 H
HDL		.000(0.000-1.571E+37)	
TC		+32(0.000-2.488E+101)	
TG		.000(0.000-1.370E+17)	
ALT	0.706	0.990(0.938-1.044)	
AST	0.659	1.024(0.921-1.140)	Т
	0.000	1.024(0.321 - 1.140)	
			1 1.427E+45
			Odd ratio




medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this Figure S3 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.










Cell type


### Cell type

-log<sub>10</sub>(P)


Oen type	
B cells naive	T cells CD4 memory resting
B cells memory	T cells CD4 memory activated
Plasma cells	T cells follicular helper
T cells CD8	T cells regulatory (Tregs)
T cells CD4 naive	T cells gamma delta
NK cells resting	Macrophages M2
NK cells resting NK cells activated	Macrophages M2 Dendritic cells resting
	1 0
NK cells activated	Dendritic cells resting
NK cells activated Monocytes	Dendritic cells resting Dendritic cells activated
NK cells activated Monocytes Macrophages M0	Dendritic cells resting Dendritic cells activated Mast cells resting




medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this Figure S5 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in



All rights reserved. No reuse allowed without permission.





P02746 C1QE O15031 PEXNB2

medRxiv preprint doi: https://doi.org/10.1101/2022.11.01.22281744; this version posted November 2, 2022. The copyright holder for this Figure S7 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.